Literature DB >> 34705118

Hyaluronan injection versus oral glucosamine and diclofenac in the treatment of temporomandibular joint osteoarthritis.

Xiao Cen1,2, Xuefeng Pan1,3, Bo Zhang1,3, Chenlu Liu1,3, Xinqi Huang4,5, Zhihe Zhao1,3.   

Abstract

OBJECTIVES: This study was aimed to compare the effects of 4 biweekly hyaluronan (HA) injection with glucosamine and diclofenac oral administration on TMJ OA patients.
MATERIALS AND METHODS: This retrospective cohort study included TMJ OA patients who had the treatment of 4 biweekly HA injection (group HA) or oral glucosamine hydrochloride for 3 months and diclofenac sodium for 2 weeks (group G/D), and had complete data at first-visit, 3 months, 6 months, and 12 months. Clinical signs and symptoms were scored by anamnestic dysfunction index (Ai) and clinical dysfunction index (Di), and condylar bone changes were evaluated by CBCT scoring system.
RESULTS: We included 22 patients in group HA and 20 patients in group G/D. After HA injection, Ai was decreased from 4.3 to 1.6(CI [- 4.0, - 1.4]) at 3-month follow-up, which was smaller than that in group G/D significantly. Di in group HA was declined significantly from 8.1 at first-visit to 3.6 at 3-month follow-up, while Di in group G/D scarcely changed until at 6- and 12-month follow-up. Neither HA injection nor oral glucosamine/diclofenac showed positive effect on the bone of TMJs during follow-ups with statistical significance.
CONCLUSIONS: HA injection alleviated signs and symptoms of TMJ OA rapidly and presented superior clinical effects over oral glucosamine with diclofenac. However, both treatments did not limit the bone destruction of TMJs significantly. CLINICAL RELEVANCE: This cohort study provides knowledge on the symptom relief and bone changes of TMJ OA patients when treated with HA injection or glucosamine and diclofenac oral administration.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Diclofenac; Glucosamine; Hyaluronan; Osteoarthritis; Temporomandibular joint

Mesh:

Substances:

Year:  2021        PMID: 34705118     DOI: 10.1007/s00784-021-04241-8

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  20 in total

1.  No effect of glucosamine sulfate on osteoarthritis in the temporomandibular joints--a randomized, controlled, short-term study.

Authors:  Birgitta Johansson Cahlin; Lars Dahlström
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2011-10-15

2.  Sleep disturbance and psychologic distress: prevalence and risk indicators for temporomandibular disorders in a Chinese population.

Authors:  Jie Lei; Mu-Qing Liu; Adrian U Jin Yap; Kai-Yuan Fu
Journal:  J Oral Facial Pain Headache       Date:  2015

3.  Association Between Clinical Signs of Temporomandibular Disorders and Psychological Distress Among an Adult Finnish Population.

Authors:  Lauri Tuuliainen; Kirsi Sipilä; Pirjo Mäki; Mauno Könönen; Anna Liisa Suominen
Journal:  J Oral Facial Pain Headache       Date:  2015

4.  A longitudinal epidemiologic study of signs and symptoms of temporomandibular disorders from 15 to 35 years of age.

Authors:  T Magnusson; I Egermark; G E Carlsson
Journal:  J Orofac Pain       Date:  2000

5.  Comparison of 2 hyaluronic acid drugs for the treatment of temporomandibular joint osteoarthritis.

Authors:  Luca Guarda-Nardini; Cristina Cadorin; Antonio Frizziero; Giuseppe Ferronato; Daniele Manfredini
Journal:  J Oral Maxillofac Surg       Date:  2012-08-29       Impact factor: 1.895

Review 6.  Hyaluronic acid in the treatment of TMJ disorders: a systematic review of the literature.

Authors:  Daniele Manfredini; Fabio Piccotti; Luca Guarda-Nardini
Journal:  Cranio       Date:  2010-07       Impact factor: 2.020

Review 7.  Hyaluronan as an immune regulator in human diseases.

Authors:  Dianhua Jiang; Jiurong Liang; Paul W Noble
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

8.  Inhibition of interleukin-1beta-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage.

Authors:  Sohel M Julovi; Tadashi Yasuda; Makoto Shimizu; Teruko Hiramitsu; Takashi Nakamura
Journal:  Arthritis Rheum       Date:  2004-02

9.  An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).

Authors:  Olivier Bruyère; Cyrus Cooper; Jean-Pierre Pelletier; Jaime Branco; Maria Luisa Brandi; Francis Guillemin; Marc C Hochberg; John A Kanis; Tore K Kvien; Johanne Martel-Pelletier; René Rizzoli; Stuart Silverman; Jean-Yves Reginster
Journal:  Semin Arthritis Rheum       Date:  2014-05-14       Impact factor: 5.532

10.  Hyaluronan Inhibits Tlr-4-Dependent RANKL Expression in Human Rheumatoid Arthritis Synovial Fibroblasts.

Authors:  Tatsuo Watanabe; Nobunori Takahashi; Shinya Hirabara; Naoki Ishiguro; Toshihisa Kojima
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.